KingMed Diagnostics H1 2026 Net Profit Up 324.27% to RMB 190 Million
KingMed Diagnostics reported H1 2026 revenue of RMB 2.884 billion and net profit attributable to shareholders of RMB 190 million, up 324.27% year-on-year. Excluding non-recurring items, net profit was RMB 203 million, up 307.38%. In Q2, revenue rose 0.19% to RMB 1.533 billion, while net profit surged 358.50% to RMB 147 million. The share of revenue from tertiary hospitals increased to 54.37%, and high-end private medical market revenue grew 63.84%. The company accelerated digital transformation, with 165 AI agents and over 40 million model calls, boosting per-capita output by 5.81%.
KingMed Diagnostics released its 2026 interim report on the evening of August 24, 2026. The report showed that in the first half of 2026, the company achieved revenue of RMB 2.884 billion; net profit attributable to shareholders was RMB 190 million, up 324.27% year-on-year; net profit attributable to shareholders excluding non-recurring items was RMB 203 million, up 307.38% year-on-year.
In the second quarter, the company achieved revenue of RMB 1.533 billion, up 0.19% year-on-year; net profit attributable to shareholders was RMB 147 million, up 358.50% year-on-year; net profit attributable to shareholders excluding non-recurring items was RMB 151 million, up 355.34% year-on-year. Both revenue and net profit posted positive growth in the second quarter.
As of the end of the reporting period, the share of revenue from tertiary hospitals increased to 54.37%, up 3.19 percentage points year-on-year, while the number of core customers rose steadily. Revenue from the high-end private medical market grew 63.84%, and the company has established partnerships with private medical institutions such as United Family Healthcare and Zhuozheng Medical.
During the reporting period, the company accelerated its digital and intelligent transformation. The Yujian Yiyan large model was upgraded, and the capabilities of the AI agent application 'Xiaoyu Yi' were enhanced. A total of 165 AI agent applications were developed, with model calls exceeding 40 million times, saving 23,000 person-days of labor and increasing overall per-capita output by 5.81%.
KingMed Cloud Inspection (KMC) surpassed 760,000 clinical physician users, with over 250,000 monthly active users. 'Xiaoyu Yi' had over 140,000 monthly active users, with application scenarios including report interpretation, medical record quality control, and intelligent medical insurance. The Yujian Yiyan large model has been listed on Sichuan Province's 'AI + Healthcare' public support service platform and included in the provincial special procurement system. The DeepGEM pathology-genomics multimodal large model, developed with Tencent and the First Affiliated Hospital of Guangzhou Medical University, has been piloted at certain medical institutions.
In the first half of 2026, the company established its medium- and long-term strategic goal of building a globally leading intelligent medical diagnostics service platform, and promoting the integration of data elements and artificial intelligence technologies into medical laboratory scenarios.